Author:

Basilea Pharmaceutica Ltd.

Date: 8 September 2005

Abstract:

No abstract, First paragraph: Basilea Pharmaceutica Ltd. announced today positive results from its phase II clinical trial evaluating BAL8557, Basilea’s broad-spectrum antifungal. The trial was conducted in patients with esophageal candidiasis, a common infection in immunocompromised patients.

Link to DOI

Download the full article (Disclaimer)

This manuscript library of ~16,000 articles (1729-2024) related to Aspergillus and aspergillosis is intended for individual study only, and is provided as contribution to global understanding of the topic. Please refer to the publisher’s guidance about any other usage.

I understand (click to accept and view download link)

---